Shares of Dimension Therapeutics, Inc. (NASDAQ:DMTX) have been given an average rating of “Hold” by the eight analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $5.08.
Several research analysts recently commented on DMTX shares. Canaccord Genuity cut Dimension Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from $12.00 to $3.41 in a research note on Wednesday, August 30th. Chardan Capital reiterated a “hold” rating on shares of Dimension Therapeutics in a research note on Monday, August 14th. Wells Fargo & Company cut Dimension Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $9.00 to $6.00 in a research note on Tuesday, October 3rd. Citigroup upgraded Dimension Therapeutics from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $5.50 to $6.00 in a research note on Tuesday, October 3rd. Finally, ValuEngine upgraded Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 30th.
A number of hedge funds and other institutional investors have recently made changes to their positions in DMTX. Goldman Sachs Group Inc. raised its stake in Dimension Therapeutics by 206.7% during the second quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 54,231 shares in the last quarter. Kassirer Asset Management Corp acquired a new stake in Dimension Therapeutics during the third quarter valued at approximately $952,000. K2 Principal Fund L.P. acquired a new stake in Dimension Therapeutics during the third quarter valued at approximately $960,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Dimension Therapeutics during the third quarter valued at approximately $600,000. Hedge funds and other institutional investors own 70.33% of the company’s stock.
Dimension Therapeutics (NASDAQ DMTX) opened at $5.95 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.33 and a current ratio of 2.01. Dimension Therapeutics has a one year low of $1.05 and a one year high of $6.10.
Dimension Therapeutics (NASDAQ:DMTX) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.20). Dimension Therapeutics had a negative return on equity of 240.95% and a negative net margin of 378.28%. The business had revenue of $4.48 million during the quarter. equities analysts anticipate that Dimension Therapeutics will post -1.99 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/09/dimension-therapeutics-inc-dmtx-given-consensus-rating-of-hold-by-analysts.html.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.